Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 19p13 3 Microduplication Syndrome C5679996
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 19p13 3 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
19p13 3 Microduplication Syndrome C5679996
A chromosomal disorder involving extra genetic material on chromosome 19. It can affect development and cause intellectual disability. Management focuses on supportive therapies and addressing specific symptoms.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
19p13 3 Microduplication Syndrome C5679996
0-null
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
19p13 3 Microduplication Syndrome C5679996
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
19p13 3 Microduplication Syndrome C5679996
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
19p13 3 Microduplication Syndrome C5679996
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
19p13 3 Microduplication Syndrome C5679996
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
19p13 3 Microduplication Syndrome C5679996
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 19p13-3-microduplication-syndrome-C5679996 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 19p13 3 Microduplication Syndrome C5679996 | Discriminating power |
|---|---|---|---|
| Developmental delay | Early neurologic delay linked to impaired serine production. | Developmental effects and intellectual disability from extra 19p13.3 material. | Moderate |
| Seizures | Described as a principal neurologic feature. | Not established as a defining feature in the supplied description. | High |
| Movement difficulty | May accompany the metabolic neurologic presentation. | Specific motor findings are not established and may vary. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Young child with seizures and developmental delay
This pattern fits the described serine-synthesis disorder better than a nonspecific chromosomal phenotype.
Moderate
Suspected inborn error of metabolism
The left condition is categorized as a metabolic disorder affecting serine production.
High
Biochemical clues suggest reduced serine-pathway activity
This supports specialist metabolic evaluation; no cutoff is supplied here.
Moderate
Choose 19p13 3 Microduplication Syndrome C5679996 when
Congenital developmental disorder without a metabolic pattern
The right condition is a chromosomal copy-number disorder rather than a serine-pathway disease.
Moderate
Intellectual disability requiring genetic evaluation
Chromosomal testing is appropriate when a microduplication is suspected.
Moderate
Concern for a 19p13.3 copy-number change
Confirmation depends on detecting extra genetic material at that region.
High
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 19p13 3 Microduplication Syndrome C5679996 | Interpretation |
|---|---|---|---|
| Amino acid analysis | Serine may be low; no numeric cutoff is provided. | Not expected to establish the chromosomal diagnosis. | An abnormal result suggests metabolic disease but is not itself a diagnosis. |
| Chromosomal microarray | Not the primary test for the enzyme deficiency. | May demonstrate a 19p13.3 microduplication. | A confirmed duplication supports the right condition. |
| PHGDH-related genetic testing | May identify the suspected enzyme deficiency when indicated. | Does not replace copy-number analysis. | Test selection should follow the suspected mechanism. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Seizure burden, developmental needs, and response to indicated care.
19p13 3 Microduplication Syndrome C5679996
- Outcome
- Described as moderate and chronic, with variable developmental impact.
- Factors
- Duplication extent and support needs are not quantified here.
Time frame: Childhood presentation with long-term follow-up; exact prognosis is unknown.
Early recognition, tailored therapy, education, and family support.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | A described neurologic complication. Not established from the supplied source. Management is individualized; no medication or dose is specified. |
| Intellectual disability | Developmental delay is described. Intellectual disability is described. Severity and long-term outcome are not quantified here. |
| Functional limitation | Movement difficulty may affect care needs. Specific physical complications are not established. Function should be assessed individually by clinicians and therapists. |
Patient education highlights
- HighDifferent causes
One impairs serine production; the other involves extra chromosome 19 material. They are not interchangeable diagnoses.
- HighAppropriate testing
Metabolic studies and chromosomal microarray answer different questions and require clinician guidance.
- MediumSupportive care
Care may include serine supplementation or seizure treatment for the left condition and symptom-focused therapies for the right.